# JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Source: https://onco.cc/trials/nct06731153/  
OnCo record `nct06731153` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of camrelizumab and eribulin in triple-negative breast cancer, run by Fudan University, not yet recruiting.

## Summary

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC is a phase 2, randomised interventional study registered as NCT06731153 by Fudan University, with a registry enrolment figure of 40 participants, started 2024-12 and due to reach its primary completion in 2027-06. Interventions recorded: Ivarmacitinib; Camrelizumab (SHR-1210); Eribulin. Conditions listed: Triple Negative Breast Cancer (TNBC); Metastatic Breast Cancer. Triple-negative eligibility wording from the registry: "Metastatic or locally advanced, histologically documented TNBC;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06731153
- Phase: 2
- Setting: A Randomized, Controlled, Open-label, Phase II Clinical Study Evaluating the JAK1 Inhibitor Ivarmacitinib to Reverse Immunotherapy Resistance in Triple-negative Breast Cancer
- Sponsor: Fudan University
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06731153: https://clinicaltrials.gov/study/NCT06731153

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Eribulin](https://onco.cc/drugs/eribulin/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06731153.json